77 results about "Cancer screening" patented technology

The invention discloses application of a gene marker in early screening of esophagus, stomach and intestine multiple cancer species, an early screening model construction method and a detection device, and belongs to the technical field of early noninvasive detection of digestive tract tumors. By analyzing the whole genome characteristics of circulating free DNA in peripheral blood, a novel multi-cancer-species screening system is established. On the basis of low-depth whole genome sequencing data, molecular markers in three dimensions, namely a genome copy number variation mode, a DNA fragment distribution characteristic with a specific length and an epigenetics signal of a transcription initiation region, are emphatically detected. An advanced converter neural network architecture is adopted, and the model can efficiently capture complex feature association in a whole genome range through a specific self-attention mechanism. The model design particularly considers the particularity of genome data, introduces an adaptive position coding system, and accurately reflects the spatial distribution relationship of DNA fragments on chromosomes. Therefore, the system can still maintain excellent detection performance under extremely low sequencing depth.

Methods for non-invasive cancer detection use a combination of genome-wide mutation and fragmentation features of cfDNA that facilitate cancer screening.

The present application relates to a lung-cancer screening model construction apparatus, a lung-cancer screening apparatus, and a device and a medium. The lung-cancer screening model construction apparatus comprises: a sample acquisition and data collection module, which is used for acquiring benign pulmonary nodule patient samples, and collecting baseline parameters of the benign pulmonary nodule patient samples, wherein the baseline parameters comprise radial growths of pulmonary nodules and serum thymidine kinase 1; a model training module, which is used for performing model training by using the baseline parameters as independent variables and using, as dependent variables, risks of lung cancer newly diagnosed within three years after baseline visits; and a model evaluation and verification module, which is used for performing prediction efficiency evaluation and internal verification on the trained model, so as to obtain a risk prediction model for newly diagnosed lung cancer of benign pulmonary nodule patients within three years. The present application can be used for predicting the risk of progression from benign pulmonary nodule to lung cancer in a large-sample Chinese population.

Disclosed herein are methods, compositions, and kits related to the identification and / or quantification of target molecules. Furthermore, the disclosure relates to compositions, kits, and methods for detecting and quantifying molecular targets, and especially for detecting and quantifying DNA and RNA The apparatuses and methods. may find use in a variety of applications including prenatal testing detection of pathogens and screening of cancer.

The present invention relates to the field of gene detection, and particularly to a primer-probe combination, a kit and their applications for detecting the benign and malignant nature of pulmonary nodules. The primer-probe combination includes primer pairs and probes for detecting gene mutation sites and methylation sites, and can achieve simultaneous detection covering the EGFR L858R mutation site, the EGFR 19Del mutation site, and the methylation sites of the HOXA7, CCNA1, and ZNF808 genes at one time. Thus, the present invention is a simple, rapid and accurate combined detection scheme for DNA methylation and gene mutation to assist in differentiating the benign and malignant nature of pulmonary nodules; at the same time, the primer-probe combination can achieve rapid pre-cancer screening, and also has application values such as accurate medication guidance and prognosis and metastasis risk prediction.

The invention discloses a method, a system, equipment and a medium for detecting an HPV (human papilloma virus) DNA (deoxyribonucleic acid) integration event, and relates to the technical field of gene detection. According to the method, HPV types and virus loads (Ct values) pre-screened by qPCR are used as natural identifiers to guide grouping and mixing of samples, and HPV integrated event detection and sample tracing are synchronously realized through single sequencing. Clinical verification shows that compared with qPCR, the comprehensive sensitivity reaches 97.1%, and the cost is reduced by 60%. And a built-in targeted retest mechanism improves the reliability of a detection result. The invention provides a novel, traceable, economical and feasible solution, is used for high-throughput HPV-host genome integration feature analysis, balances cost, expandability and clinical accuracy, and provides a high-throughput and low-cost solution for HPV-related cancer screening.

To provide a method for screening an olfactory receptor protein or its combination useful in cancer examination.SOLUTION: A method for screening an olfactory receptor protein or a combination thereof, comprising testing the reactivity of a test olfactory receptor protein to cancer, and selecting at least one selected from the group consisting of (1) a combination of the olfactory receptor protein A and the olfactory receptor protein C, (2) a combination of the olfactory receptor protein A ' and the olfactory receptor protein B, and (3) the olfactory receptor protein B '.SELECTED DRAWING: None

Methods and systems for detection and diagnosis of oral lesions and application of treatment are described. One example mobile intraoral system includes an intraoral probe with a plurality of windows and a first plurality of light sources positioned in its distal section. The intraoral probe also includes one or more additional light sources operable at one or more wavelengths in the range 600 nm to 700 nm, one or more heat sinks, and one or more optical waveguides coupled to the additional light sources. The mobile intraoral system is selectively operable in a first mode of operation for imaging and diagnosis of suspicious regions in the oral cavity, and a second mode of operation for administering photodynamic therapy (PDT). The intraoral probe's distal section is bendable to allow insertion in the oral cavity and targeting a particular location of the oral cavity for administration of the PDT.

A multi-modality cancer screening and diagnosis system is provided that allows cancer screening and diagnosis of a patient using at least two different and sequential three-dimensional imaging techniques without patient repositioning. The system includes a first three-dimensional image acquisition device, a second three-dimensional image acquisition device having a probe with a transmitter mounted thereon, and a positioning paddle for positioning and immobilizing an object to be imaged during the cancer screening and diagnosis procedure. The positioning paddle is designed to facilitate visualization of the breast in both three-dimensional modalities without movement of the patient, and preferably is designed to position the patient with comfort during a diagnosis procedure which uses both imaging modalities.

The embodiment of the invention provides an image processing method and a CT image processing method, and the image processing method comprises the steps: receiving an image processing task which carries a plurality of target images which comprise at least one to-be-detected region, the image processing task is used for determining whether an abnormal object exists in each to-be-detected area; and inputting the plurality of target images into an image processing model to obtain a detection result corresponding to each to-be-detected area, the detection result including detection labeling information, detection category information and a detection guidance text. According to the method, efficient abnormal object recognition can be performed on multiple to-be-detected areas in the target image, the detection efficiency and accuracy are improved, and the problems of missing detection and false detection in a traditional method can be avoided. The multi-cancer screening can be realized, meanwhile, a clearer, more visual and interpretable auxiliary diagnosis basis can be provided for medical personnel, and the convenience and decision-making quality of clinical work are improved.

Disclosed is a machine learning method for curating biomarker panel, for screening of cancer(s) and system therefor, addressing the critical need for early detection through a combination of innovative biomarker research, advanced computational algorithms and integration with existing healthcare infrastructure. The biomarker panel is curated to facilitate pan-cancer screening of the patient with high sensitivity and specificity using the ML method deploying MoE (Mixture of Expert) models for accurate screening, thereby enhancing diagnostic accuracy and also empowering clinicians with actionable insights, thereby improving patient prognosis and facilitating personalized treatment strategies.

The invention provides a biomarker and a kit for pancreatic cancer screening, and belongs to the technical field of cancer screening. According to the technical scheme, urine proteins of pancreatic cancer patients are screened in a large range, early pancreatic cancer patients are taken as target samples, two specific amino acid fragments are determined, the content of the two specific amino acid fragments in non-pancreatic cancer patients is extremely low, the two specific amino acid fragments are only massively expressed in the patients, and the two specific amino acid fragments can be accurately detected in urine of the early pancreatic cancer patients. Benefited from the specific markers, the invention designs a kit and a detection method for pancreatic cancer screening, according to the method, urine total protein is extracted, enzymolysis, desalination and drying are performed, liquid chromatography-mass spectrometry analysis is performed, and whether a target peak appears on a chromatogram or not is taken as a judgment basis. The screening scheme is high in specificity and sensitivity, simple and convenient to operate, capable of effectively improving the discovery rate of the early pancreatic cancer and good in popularization prospect.

Methods for creating a selector of mutated genomic regions and for using the selector set to analyze genetic alterations in a cell-free nucleic acid sample are provided. The methods can be used to measure tumor-derived nucleic acids in a blood sample from a subject and thus to monitor the progression of disease in the subject. The methods can also be used for cancer screening, cancer diagnosis, cancer prognosis, and cancer therapy designation.

Cell-free DNA molecules in a mixture of a biological sample can be analyzed to detect viral DNA. Methylation of viral DNA molecules at one or more sites in the viral genome can be determined. Mixture methylation level(s) can be measured based on one or more amounts of the plurality of cell-free DNA molecules methylated at a set of site(s) of the particular viral genome. The mixture methylation level(s) can be determined in various ways, e.g., as a density of cell-free DNA molecules that are methylated at a site or across multiple sites or regions. The mixture methylation level(s) can be compared to reference methylation level(s), e.g., determined from at least two cohorts of other subjects. The cohorts can have different classifications (including the first condition) associated with the particular viral genome. A first classification of whether the subject has the first condition can be determined based on the comparing.

The present invention relates to a method for detecting a specific component in a biological sample (e.g., a blood sample) obtained from a subject in order to predict whether the subject has cancer. The present invention provides a method comprising isolating one or more components selected from the group consisting of SerpinA3 and Gal3BP from the biological sample. The present invention also provides a method comprising detecting a glycoprotein in a biological sample (e.g., a blood sample) obtained from a subject by performing an assay using a first molecule selected from the group consisting of a molecule that binds to a BC2LCN-binding sugar chain, a molecule that binds to SerpinA3, and a molecule that binds to Gal3BP, and a second molecule that binds to a BC2LCN-binding sugar chain.

The present invention relates to storing and testing for abnormalities in cell free DNA (cfDNA) from blood, such as in maternal blood or blood for cancer screening.

Methods of using detection of PD-L1 expression by circulating cancer cells in the screening, monitoring, treatment and diagnosis of cancer in subjects are disclosed. The methods are based on assaying one or more of circulating tumor cells (CTCs), epithelial to mesenchymal transition CTCs (EMTCTCs), cancer associated macrophage-like cells (CAMLs), and cancer associated vascular endothelial cells (CAVEs) isolated from a subject having cancer for PD-L1 expression.

A method for liver cancer detection uses a combination of whole genome mutations and fragmentation characteristics of cfDNA to facilitate cancer screening.

Provided herein are kits and methods useful for cancer screening, diagnosis, research and therapy. In particular, provided herein are methods of screening, diagnosing, and / or treating prostate cancer based on expression levels of cancer markers.

The present invention relates to a method of screening for or surveillance of a disease or cancer in a biological sample obtained from an individual, comprising detecting the presence of one or more disease or cancer biomarkers on or in extracellular vesicles particles (EPs) in an enriched fraction of EPs which are secreted or released from cells of a tissue of a defined category. The method of screening for or surveillance of a disease or cancer comprises obtaining an enriched fraction of EPs from a particular tissue, and detecting the presence of one or more disease or cancer biomarkers on or in EPs in the enriched fraction of EPs. Also provided are a method of identifying a disease or cancer biomarker present at reduced or elevated level on or in EPs in an enriched fraction of EPs which are secreted or released from cells of a tissue of a defined category, a system for analysing a biological sample obtained from an individual comprising an biomarker detection subsystem and a processor couplable to the biomarker detection subsystem, a use of one or more cancer biomarkers in the detection of cancer in a biological sample obtained from an individual, and an antibody and a primer, and uses thereof, for the detection of cancer of a tissue of a defined category in a biological sample obtained from an individual.

Disclosed is the characterization of nucleic acids obtained from cancer-associated cells circulating in the blood of a subject, and the use of such characterization in the screening, diagnosis, treatment, and recurrence of cancer. [Selection diagram] Figure 4

Controls for the identification of various genotypes and / or for the identification or characterization of a disease or condition are described. These controls can be especially useful for diagnostic tests that use circulating cell-free DNA or microRNA. A control may consist of a mixture of nucleic acids. In some formulations, a control comprises liposomes, for example, where the nucleic acids of the control are associated with the liposomes. For example, controls are useful for determining whether a fetus has aneuploidy. Methods for using these controls are also described.

The present invention provides a combination of epithelial and stromal biomarkers that are useful for determining whether a subject has a high or low probability of developing a tumor.In particular, the present invention provides a method for screening, detecting or monitoring tumors in a subject, the method comprising combining the expression levels of KRT19 and COL1A2 to generate a score, and determining whether a subject has a high or low probability of developing a tumor based on the score.

A method for pre-screening a subject for cancer is disclosed. Genetic risk associated with a gene signature is calculated by sequencing and analyzing cell-free DNA ("cfDNA") fragments present in a subject's blood sample. Clinical risk is calculated based on factors such as age, sex, and race. In some cases, clinical factors specific to a particular cancer, such as smoking status, are also incorporated. Incorporating clinical risk into genomic risk analysis improves lung cancer pre-screening results, enabling the detection of the same number of positive cancers using fewer LDCT lung cancer screening sessions.

The invention discloses a visual paper-based cancer miRNA marker detection kit, the kit comprises an integrally formed foldable T-shaped filter paper, and a DNA probe TEprobe, urease and a color developing agent dropwise added on the filter paper, and the principle of the kit is as follows: the TEprobe is combined with a cancer nucleic acid marker (miRNA) to release Ag < + > to inhibit the activity of the urease; the composite signal response of the pH response probe phenol red and fluorescein is triggered, and the detection sensitivity is as low as 10-12 M. The kit provided by the invention can significantly shorten the detection time and reduce the sample demand, and realizes zero false positive rate and 97.10% specificity by combining with machine learning algorithm classification during result analysis. The performance is successfully verified in real samples of prostatic cancer, liver cancer and colorectal cancer, and a cheap and convenient means is expected to be provided for family self-inspection and cancer screening and diagnosis in resource-deficient areas.

The invention discloses a liver cancer screening system based on platelet alpha particle super-resolution imaging, which combines the proportion of alpha particle'regular distribution 'platelets and clinical indexes AFP and DCP to screen liver cancer, and can improve the sensitivity of early hepatocellular carcinoma screening. Besides, according to the cancer broad-spectrum screening system provided by the invention, the proportion of alpha-particle'regular distribution 'platelets or the proportion of alpha-particle'N < = 30' platelets is taken as a cancer broad-spectrum screening marker, and the higher the proportion of the alpha-particle'regular distribution 'platelets or the lower the proportion of alpha-particle'N < = 30' platelets is, the higher the proportion of alpha-particle'regular distribution 'platelets is or the lower the proportion of alpha-particle'N < = 30' platelets is. When the cancer risk is higher, cancer broad-spectrum screening is carried out, and high specificity and sensitivity are achieved.

Described herein is a method of cancer screening with high sensitivity and high specificity to detect indicia of subclinical cancer in potential blood and organ donors prior to donation to reduce cancer transmission between donors and recipients.

The invention provides an EB (Epstein-Barr) virus DNA (Deoxyribose Nucleic Acid) and tumor high-frequency mutant gene capturing and sequencing method and application, the capturing and sequencing method comprises the following steps: (1) acquiring a plasma sample, and extracting plasma cfDNA; (2) constructing a plasma cfDNA DNA library; (3) constructing a plasma cfDNA DNA capture library; and (4) sequencing. According to the invention, a DNA capture probe mixture aiming at seven EB virus subtypes and a proper number of specific human tumor related genes is creatively used for capturing and sequencing the sample to be detected, and the method has higher sensitivity and specificity for detection of EBV DNA in the sample. Moreover, based on the fragment length ratio of EBV DNA to 100 human tumor related genes cfDNA and the content of EBV DNA, the sensitivity, specificity and accuracy of nasopharyngeal carcinoma diagnosis can be further improved. In addition, the invention not only can be used for screening EBV-related tumors, but also can be used for screening generic cancer.